Summit Therapeutics (SMMT) Return on Invested Capital (2018 - 2020)

Summit Therapeutics (SMMT) has reported Return on Invested Capital for 3 consecutive years, with 0.05% the latest figure, recorded in Q3 2020.

• Quarterly Return on Invested Capital changed 0.0% year-over-year to 0.05% in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 0.05% (changed 0.0% YoY) and the FY2019 annual result came in at 0.08%, changed N/A from the prior year.
• Return on Invested Capital improved to 0.05% in Q3 2020 per SMMT's latest filing, from 0.06% in the prior quarter.
• Over the last five years, Return on Invested Capital for SMMT reached as high as 1.97% in Q4 2018 and fell as low as 0.67% in Q3 2018.
• A 3-year average of 0.01% and a median of 0.07% in 2019 frame the typical range for Return on Invested Capital.
• The largest YoY upside for Return on Invested Capital was 60 bps in 2019 against a maximum downside of 206 bps in 2019.
• Year by year, Return on Invested Capital stood at 1.97% in 2018, then sank by 104 bps to 0.07% in 2019, then climbed by 25 bps to 0.05% in 2020.
• According to Business Quant data, Return on Invested Capital over the past three periods registered 0.05%, 0.06%, and 0.05% for Q3 2020, Q2 2020, and Q1 2020 respectively.